Clinical Trial Update: Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial studying Pentasa for reducing residual systemic immune activation in treated HIV infection and gut inflammation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gut Inflammation
• HIV Infection

Drugs mentioned

• PENTASA (MESALAMINE)

Snippet

Sponsor: AIDS Healthcare Foundation | Conditions: HIV-1-infection, Gut Inflammation | Phase 1, Phase 2 | Status: COMPLETED